What it is
Cerebrolysin is not a single peptide. It is a solution made by breaking down purified pig brain protein with enzymes, leaving a mixture of small peptides and free amino acids. It is made by the Austrian company EVER Pharma and supplied in ampoules for injection or infusion.
That makes it the odd one out in this library. Unlike Semax or Dihexa, it is a licensed prescription medicine in a number of countries, including the Philippines. Its labelled uses cover Alzheimer's dementia, vascular dementia, stroke and head injury. It is not approved in the United States, and the manufacturer says so on its own site.
Because it is a hospital drug given by drip or injection, it is not something people use as a home "nootropic". It belongs on this site because it is often mentioned alongside the cognitive peptides, and because its evidence base is far larger, and more sobering, than theirs.
How it works
The manufacturer describes it as a "multimodal" drug that supports the brain's own repair processes. The proposed mechanism is that fragments in the mixture mimic the action of natural neurotrophic factors, the signalling proteins that keep neurons alive and help them form connections. Preclinical studies in models of ischaemia reported neuroprotective effects, which is what prompted the large stroke trials.
Because the product is a mixture, it has been hard to pin down exactly which components are active, and it has no single half-life or receptor target in the way a defined peptide does.
What the research found
Stroke
- CASTA (Heiss and colleagues, 2012) is the largest trial. It randomised 1,070 people with acute ischaemic stroke in Asia to Cerebrolysin or saline for 10 days, on top of aspirin, and followed them for 90 days. The main combined outcome showed no significant difference. A post hoc look at the most severe strokes found a trend in favour of Cerebrolysin, which the authors said needed confirming in a new trial.
- The Cochrane review (Ziganshina and colleagues, 2023) pooled seven trials with 1,773 participants. Cerebrolysin probably makes little or no difference to all-cause death (risk ratio 0.96), rated moderate certainty. It made little or no difference to total serious adverse events, but non-fatal serious adverse events were higher with Cerebrolysin (risk ratio 2.39). None of the trials reported death or dependence at the end of follow-up, the outcome that matters most after a stroke. Three of the included studies had manufacturer involvement.
Dementia
- The Cochrane review of vascular dementia (Cui and colleagues, 2019) found six trials with 597 participants, mostly in China. Pooled results favoured Cerebrolysin on cognition and global function, but every outcome was rated very low quality, trials were at high risk of bias, and the authors concluded that any benefit may be too small to be clinically meaningful.
The Philippine assessment
In 2023 the Department of Health's Health Technology Assessment Council reviewed the evidence for Cerebrolysin after ischaemic stroke. It judged the efficacy evidence as low certainty, found insufficient evidence to assess safety, and recommended against government financing through the Philippine National Formulary. The Council estimated the drug cost of one course at ₱40,698 per patient, based on 30 mL daily for 21 days at ₱646 per ampoule.
Side effects reported in studies
The manufacturer describes reported reactions as mostly transient and mild. Its listed contraindications are allergy to any component, epilepsy and severe kidney impairment. The Cochrane stroke review is the more important safety signal: an increase in non-fatal serious adverse events compared with control, on moderate-certainty evidence. The Philippine HTA Council described the safety evidence as insufficient to draw conclusions.
Cerebrolysin vs Semax
| Cerebrolysin | Semax | |
|---|---|---|
| What it is | Pig brain peptide mixture | Single synthetic 7 amino acid peptide |
| Route | IV infusion or injection | Nasal drops |
| Where approved | Several countries, including the Philippines | Russia |
| Best evidence | Large RCTs and Cochrane reviews, mostly neutral | Russian clinical studies |
See also Semax vs Selank and best peptides for brain function.
Status in the Philippines
Cerebrolysin is registered with FDA Philippines as a prescription medicine, so it can be legally sold by pharmacies on prescription and used in hospitals. It is not in the Philippine National Formulary, which limits government coverage. Prescribing belongs with a licensed Philippine physician, usually a neurologist. Product sold outside the pharmacy chain as a "research peptide" is a different matter: an injectable made from animal tissue carries infection and sterility risks that only a regulated supply chain controls.
Storage
Keep ampoules in their carton as the pack label directs, protected from light and heat. In a hospital this is handled by the pharmacy; at home, a Philippine summer room or a car during a brownout is not a safe place for injectable medicines.
